PD-1 ligand (PD-L1) expression in tumor and immune cells has been reported to correlate with the therapeutic effect of PD-1/PD-L1 inhibitors in head and neck cancer, and is currently the only U.S. Food and Drug Administration (FDA)-approved biomarker (6). The gene discussed is CD274; the disease is neoplasm.